- $2.38bn
- $1.91bn
- $1.66bn
- 90
- 36
- 98
- 88
2019 September 28th | 2020 October 3rd | 2021 October 2nd | 2022 October 1st | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,261 | 1,326 | 1,717 | 1,752 | 1,655 |
Cost of Revenue | |||||
Gross Profit | 527 | 572 | 810 | 796 | 716 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,255 | 1,354 | 1,562 | 1,663 | 1,676 |
Operating Profit | 5.7 | -27.2 | 155 | 89.5 | -20.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.08 | -20.1 | 157 | 68.7 | 4.39 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.77 | -20.1 | 159 | 67.4 | -10.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.77 | -20.1 | 159 | 67.4 | -10.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.77 | -20.1 | 159 | 67.4 | -10.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.041 | 0.098 | 1.28 | 0.66 | 0.167 |